Loading...

Incyte

DB:ICY
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ICY
DB
$16B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The last earnings update was 64 days ago. More info.


Add to Portfolio Compare Print
ICY Share Price and Events
7 Day Returns
-7.5%
DB:ICY
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
18.3%
DB:ICY
-10.6%
DE Biotechs
-6.2%
DE Market
ICY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Incyte (ICY) -7.5% -13.6% -4.3% 18.3% -4.9% 95.5%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • ICY outperformed the Biotechs industry which returned -10.6% over the past year.
  • ICY outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
ICY
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Incyte undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Incyte to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Incyte.

DB:ICY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 21 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:ICY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0.23%))
1.302
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.302 * 5.96%)
7.99%

Discounted Cash Flow Calculation for DB:ICY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Incyte is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:ICY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.99%)
2019 313.25 Analyst x4 290.08
2020 565.60 Analyst x5 485.04
2021 932.67 Analyst x3 740.68
2022 1,213.67 Analyst x3 892.55
2023 1,509.33 Analyst x3 1,027.91
2024 1,739.96 Est @ 15.28% 1,097.34
2025 1,927.25 Est @ 10.76% 1,125.58
2026 2,073.79 Est @ 7.6% 1,121.59
2027 2,185.58 Est @ 5.39% 1,094.64
2028 2,269.55 Est @ 3.84% 1,052.64
Present value of next 10 years cash flows $8,928.05
DB:ICY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2,269.55 × (1 + 0.23%) ÷ (7.99% – 0.23%)
$29,322.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $29,322.28 ÷ (1 + 7.99%)10
$13,599.92
DB:ICY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $8,928.05 + $13,599.92
$22,527.98
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $22,527.98 / 214.26
$105.14
DB:ICY Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:ICY represents 0.89237x of NasdaqGS:INCY
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89237x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 105.14 x 0.89237
€93.82
Value per share (EUR) From above. €93.82
Current discount Discount to share price of €66.00
= -1 x (€66.00 - €93.82) / €93.82
29.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Incyte is available for.
Intrinsic value
30%
Share price is €66 vs Future cash flow value of €93.82
Current Discount Checks
For Incyte to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Incyte's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Incyte's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Incyte's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Incyte's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ICY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.52
NasdaqGS:INCY Share Price ** NasdaqGS (2019-04-18) in USD $73.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Incyte.

DB:ICY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INCY Share Price ÷ EPS (both in USD)

= 73.96 ÷ 0.52

143.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Incyte is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Incyte is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Incyte's expected growth come at a high price?
Raw Data
DB:ICY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 143.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts
34.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:ICY PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 143.46x ÷ 34.2%

4.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Incyte is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Incyte's assets?
Raw Data
DB:ICY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $9.03
NasdaqGS:INCY Share Price * NasdaqGS (2019-04-18) in USD $73.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:ICY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INCY Share Price ÷ Book Value per Share (both in USD)

= 73.96 ÷ 9.03

8.19x

* Primary Listing of Incyte.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Incyte is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Incyte's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Incyte has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Incyte expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Incyte expected to grow at an attractive rate?
  • Incyte's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Incyte's earnings growth is expected to exceed the Germany market average.
  • Incyte's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:ICY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ICY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts 34.2%
DB:ICY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 21 Analysts 14.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ICY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ICY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 3,711 1,999 555 10
2022-12-31 3,318 1,645 911 12
2021-12-31 2,792 1,154 635 16
2020-12-31 2,394 788 444 21
2019-12-31 2,064 496 268 21
DB:ICY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,882 336 109
2018-09-30 1,798 163 -109
2018-06-30 1,729 17 -102
2018-03-31 1,534 101 -167
2017-12-31 1,536 -93 -313
2017-09-30 1,419 91 -155
2017-06-30 1,306 133 -154
2017-03-31 1,226 34 -107
2016-12-31 1,106 305 104
2016-09-30 1,023 280 151
2016-06-30 941 193 74
2016-03-31 858 189 49

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Incyte's earnings are expected to grow significantly at over 20% yearly.
  • Incyte's revenue is expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ICY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below

All data from Incyte Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ICY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.39 7.88 2.05 7.00
2022-12-31 4.42 6.26 1.85 9.00
2021-12-31 2.99 4.32 1.65 13.00
2020-12-31 2.02 2.91 1.24 17.00
2019-12-31 1.24 1.75 0.81 17.00
DB:ICY Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.52
2018-09-30 -0.52
2018-06-30 -0.49
2018-03-31 -0.80
2017-12-31 -1.53
2017-09-30 -0.78
2017-06-30 -0.79
2017-03-31 -0.56
2016-12-31 0.55
2016-09-30 0.80
2016-06-30 0.40
2016-03-31 0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Incyte is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Incyte's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Incyte has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Incyte performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Incyte's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Incyte's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Incyte has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Incyte has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Incyte's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Incyte Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ICY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,881.88 109.49 434.93
2018-09-30 1,797.64 -109.20 424.11
2018-06-30 1,729.49 -102.32 418.78
2018-03-31 1,534.42 -167.20 400.68
2017-12-31 1,536.22 -313.14 366.63
2017-09-30 1,418.56 -154.64 363.22
2017-06-30 1,306.49 -153.82 347.67
2017-03-31 1,226.34 -106.91 324.28
2016-12-31 1,105.72 104.22 301.67
2016-09-30 1,023.10 150.53 259.64
2016-06-30 941.24 74.07 231.46
2016-03-31 857.94 48.94 216.34
2015-12-31 753.75 6.53 196.61
2015-09-30 633.84 -85.59 192.60
2015-06-30 644.38 13.29 184.45
2015-03-31 580.98 -32.88 173.67
2014-12-31 511.50 -48.48 165.77
2014-09-30 484.59 -54.41 155.35
2014-06-30 371.57 -135.74 142.35
2014-03-31 373.66 -101.44 124.70
2013-12-31 354.95 -83.15 109.98
2013-09-30 371.72 -21.50 95.69
2013-06-30 347.09 -21.17 89.76
2013-03-31 331.96 -14.56 86.23
2012-12-31 297.06 -44.32 85.36
2012-09-30 212.10 -118.18 82.79
2012-06-30 168.39 -149.55 76.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Incyte has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Incyte used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Incyte has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Incyte's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Incyte has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Incyte's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Incyte's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Incyte is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Incyte's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Incyte's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 50.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Incyte Company Filings, last reported 3 months ago.

DB:ICY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,925.97 36.13 1,438.32
2018-09-30 1,802.90 24.87 1,375.31
2018-06-30 1,732.92 24.57 1,198.38
2018-03-31 1,628.04 24.27 1,171.06
2017-12-31 1,630.63 24.00 1,169.65
2017-09-30 1,757.75 23.71 1,281.39
2017-06-30 1,026.84 23.43 608.61
2017-03-31 965.93 41.60 511.96
2016-12-31 419.47 651.48 808.55
2016-09-30 369.99 643.43 716.59
2016-06-30 297.06 635.49 629.19
2016-03-31 227.75 627.64 810.67
2015-12-31 171.16 619.89 707.78
2015-09-30 88.74 623.93 635.05
2015-06-30 55.17 659.97 627.47
2015-03-31 -41.41 697.55 585.42
2014-12-31 -81.63 675.17 600.26
2014-09-30 -89.59 730.21 532.36
2014-06-30 -171.00 712.22 508.75
2014-03-31 -162.42 695.12 519.23
2013-12-31 -193.11 661.57 509.00
2013-09-30 28.79 187.14 291.17
2013-06-30 -27.79 223.82 277.45
2013-03-31 -163.53 337.51 270.18
2012-12-31 -174.96 331.08 228.42
2012-09-30 -219.95 334.60 243.60
2012-06-30 -217.19 328.31 261.81
  • Incyte's level of debt (1.9%) compared to net worth is satisfactory (less than 40%).
  • Incyte had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (930.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 100.4x coverage).
X
Financial health checks
We assess Incyte's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Incyte has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Incyte's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Incyte dividends. Estimated to be 0% next year.
If you bought €2,000 of Incyte shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Incyte's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Incyte's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ICY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ICY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Incyte has not reported any payouts.
  • Unable to verify if Incyte's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Incyte's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Incyte has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Incyte's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Incyte's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Incyte afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Incyte has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Incyte's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hervé Hoppenot
COMPENSATION $9,314,189
AGE 58
TENURE AS CEO 5.3 years
CEO Bio

Mr. Hervé Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commercial Officer and Head of Global Product Strategy & Scientific Development at Incyte Corporation, where he oversaw medical affairs, global brand leadership, business development and licensing, health economics & pricing, early phase commercial development, strategic capabilities and global sales excellence for Oncology. He joined Novartis in 2003 and served as its Senior Vice President and Head of Global Marketing from 2003 to September 2006. He was responsible for translational medicine, development, approval and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry and 8,000 employees in 50 countries. He has more than twenty-five years of international experience. He started his career in France with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot has been a Director of Incyte Corporation since January 13, 2014. Mr. Hoppenot served as the President of Novartis Oncology from January 2010 to January 2014. Prior to that, Mr. Hoppenot served in other executive positions at Novartis Pharmaceuticals Corporation, serving from September 2006 to January 2010 as Executive Vice President, Chief Commercial Officer of Novartis Oncology and Head of Global Product Strategy & Scientific Development of Novartis Pharmaceuticals Corporation. Prior to joining Novartis, Mr. Hoppenot served in various increasingly senior roles at Aventis S.A. (formerly Rhône-Poulenc S.A.), a pharmaceutical company, including as Vice President Oncology US of Aventis Pharmaceuticals, Inc. from 2000 to 2003 and Vice President US Oncology Operations of Rhone-Poulenc Rorer Pharmaceuticals, Inc. from 1998 to 2000. Mr. Hoppenot is also a director of Cellectis S.A. He holds a Diploma from ESSEC International Business School.

CEO Compensation
  • Hervé's compensation has been consistent with company performance over the past year.
  • Hervé's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Incyte management team in years:

3.3
Average Tenure
51
Average Age
  • The tenure for the Incyte management team is about average.
Management Team

Hervé Hoppenot

TITLE
Chairman
COMPENSATION
$9M
AGE
58
TENURE
5.3 yrs

Maria Pasquale

TITLE
Executive VP & General Counsel
COMPENSATION
$4M
TENURE
1 yrs

Wenqing Yao

TITLE
Executive VP & Head of Discovery Chemistry
COMPENSATION
$7M
AGE
55
TENURE
4.5 yrs

Steven Stein

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$7M
AGE
51
TENURE
4.1 yrs

Christiana Stamoulis

TITLE
Executive VP & CFO
AGE
47
TENURE
0.2 yrs

Michael Morrissey

TITLE
Head of Global Technical Operations & Corporate Senior VP
TENURE
3.3 yrs

Dashyant Dhanak

TITLE
Executive VP & Chief Scientific Officer
TENURE
0.3 yrs

Mike Booth

TITLE
Vice President of Investor Relations
AGE
47
TENURE
5.1 yrs

Pamela Murphy

TITLE
Vice President of Investor Relations & Corporate Communications
AGE
67

Vijay Iyengar

TITLE
Executive VP of Global Strategy & Corporate Development
AGE
45
TENURE
2.9 yrs
Board of Directors Tenure

Average tenure and age of the Incyte board of directors in years:

4.8
Average Tenure
60.5
Average Age
  • The tenure for the Incyte board of directors is about average.
Board of Directors

Hervé Hoppenot

TITLE
Chairman
COMPENSATION
$9M
AGE
58
TENURE
3.9 yrs

Jim Baker

TITLE
Vice Chairman & Lead Independent Director
COMPENSATION
$503K
AGE
51
TENURE
5.3 yrs

Paul Brooke

TITLE
Independent Director
COMPENSATION
$522K
AGE
72
TENURE
18.3 yrs

Paul Clancy

TITLE
Independent Director
COMPENSATION
$497K
AGE
56
TENURE
4.3 yrs

Paul Friedman

TITLE
Independent Director
COMPENSATION
$477K
AGE
75
TENURE
17.4 yrs

Wendy Dixon

TITLE
Independent Director
COMPENSATION
$492K
AGE
63
TENURE
8.9 yrs

Jean-Jacques Bienaimé

TITLE
Independent Director
COMPENSATION
$485K
AGE
65
TENURE
4.3 yrs

Jackie Fouse

TITLE
Independent Director
COMPENSATION
$477K
AGE
57
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Nov 18 Buy Jean-Jacques Bienaimé Individual 08. Nov 18 08. Nov 18 1,000 €60.35 €60,224
03. May 18 Buy Hervé Hoppenot Individual 02. May 18 02. May 18 15,000 €50.90 €763,548
X
Management checks
We assess Incyte's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Incyte has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Details
Name: Incyte Corporation
ICY
Exchange: DB
Founded: 1991
$14,097,495,128
214,264,527
Website: http://www.incyte.com
Address: Incyte Corporation
1801 Augustine Cut-Off,
Wilmington,
Delaware, 19803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INCY Common Shares Nasdaq Global Select US USD 04. Nov 1993
DB ICY Common Shares Deutsche Boerse AG DE EUR 04. Nov 1993
LSE 0J9P Common Shares London Stock Exchange GB USD 04. Nov 1993
WBAG INCY Common Shares Wiener Boerse AG AT EUR 04. Nov 1993
Number of employees
Current staff
Staff numbers
1,367
Incyte employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:33
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/19
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.